Related Experiment Video

Updated: Jun 9, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Aliskiren: beyond blood pressure reduction

Graziano Riccioni1, Nicola Vitulano, Alessandra Zanasi

  • 1Cardiology Unit, San Camillo Hospital, via Isonzo, 71043 Manfredonia, Foggia, Italy. griccioni@hotmail.com

Expert Opinion on Investigational Drugs
|September 4, 2010
PubMed

Insights

Aliskiren, a renin inhibitor, effectively controls blood pressure and may offer benefits beyond hypertension, potentially impacting atherosclerosis and cardiovascular risk in various conditions.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Hypertension is a primary risk factor for cardiovascular disease (CVD).
  • Renin-angiotensin-aldosterone system (RAAS) inhibitors, including ACE inhibitors and ARBs, are crucial for blood pressure management and organ function.
  • Understanding RAAS pathways is key to managing complex cardiovascular conditions.

Purpose of the Study:

  • To review the effectiveness and safety of aliskiren beyond its role in hypertension treatment.
  • To explore aliskiren's potential in managing conditions associated with increased cardiovascular risk.
  • To evaluate aliskiren's broader therapeutic applications.

Main Methods:

  • This is a review article.
  • Focuses on existing literature regarding aliskiren's efficacy and safety.
  • Analyzes aliskiren's mechanism of action and potential clinical applications.

Main Results:

  • Aliskiren is the first approved direct renin inhibitor, blocking angiotensin I generation.
  • Its mechanism suggests potential to inhibit atherosclerosis progression at the tissue level.
  • Aliskiren may be beneficial in conditions like stable coronary artery disease (CAD), cardio-renal disease, diabetes, and peripheral arterial disease (PAD).

Conclusions:

  • Enhanced blockade of the RAAS through therapies like aliskiren can lead to improved outcomes in hypertension-related organ damage.
  • Aliskiren presents a potential therapeutic option for a wide range of cardiovascular conditions.
  • Further research may elucidate aliskiren's full potential in managing complex diseases.
Abstract

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...